Methods of treating tardive dyskinesia using NMDA receptor antagonists
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 2, 1999
Grant Date -
N/A
app pub date -
May 22, 1997
filing date -
May 22, 1997
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method for treating symptoms of patients diagnosed with tardive dyskinesia (TD) using NMDA receptor antagonists is disclosed. This invention illustrates that certain NMDA-receptor antagonists are effective pharmacologic agents in the treatment of hyperkinesia and cognitive disorders that present in patients diagnosed with TD. The disclosed agents reduce the severity and duration of involuntary movements associated with tardive dyskinesia. Certain of the disclosed agents are also effective in increasing the attention span, concentration span, memory and everyday functional performance as measured both subjectively as well as objectively as demonstrated using standard neuropsychological tests such as those assessing reaction time and short-term memory. The invention also discloses a method of treating tardive dyskinesia that acts in a neuroprotective manner to reduce or prevent glutamate-related excitotoxic damage to the basal ganglia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully